Trakya University Hospital, Department of Radiation Oncology, Edirne, Turkey.
Radiat Oncol. 2011 Mar 30;6:28. doi: 10.1186/1748-717X-6-28.
We aimed to evaluate retrospectively the correlation of loco-regional relapse (LRR) rate, distant metastasis (DM) rate, disease free survival (DFS) and overall survival (OS) in a group of breast cancer (BC) patients who are at intermediate risk for LRR (T1-2 tumor and 1-3 positive axillary nodes) treated with or without postmastectomy radiotherapy (PMRT) following modified radical mastectomy (MRM).
Ninety patients, with T1-T2 tumor, and 1-3 positive nodes who had undergone MRM received adjuvant systemic therapy with (n = 66) or without (n = 24) PMRT. Patient-related characteristics (age, menopausal status, pathological stage/tumor size, tumor location, histology, estrogen/progesterone receptor status, histological grade, nuclear grade, extracapsular extension, lymphatic, vascular and perineural invasion and ratio of involved nodes/dissected nodes) and treatment-related factors (PMRT, chemotherapy and hormonal therapy) were evaluated in terms of LRR and DM rate. The 5-year Kaplan-Meier DFS and OS rates were analysed.
Differences between RT and no-RT groups were statistically significant for all comparisons in favor of RT group except OS: LRR rate (3% vs 17%, p = 0.038), DM rate (12% vs 42%, p = 0.004), 5 year DFS (82.4% vs 52.4%, p = 0.034), 5 year OS (90.2% vs 61.9%, p = 0.087). In multivariate analysis DM and lymphatic invasion were independent poor prognostic factors for OS.
PMRT for T1-2, N1-3 positive BC patients has to be reconsidered according to the prognostic factors and the decision has to be made individually with the consideration of long-term morbidity and with the patient approval.
我们旨在评估一组局部区域复发(LRR)率、远处转移(DM)率、无病生存(DFS)和总生存(OS)与接受或不接受改良根治术后放疗(PMRT)的 T1-2 肿瘤和 1-3 阳性腋窝淋巴结的乳腺癌(BC)患者的相关性。这些患者为局部区域复发高危(LRR)患者。
90 例 T1-T2 肿瘤和 1-3 个阳性淋巴结的患者接受改良根治术后接受辅助全身治疗,其中 66 例患者接受 PMRT,24 例患者未接受 PMRT。评估患者相关特征(年龄、绝经状态、病理分期/肿瘤大小、肿瘤位置、组织学、雌激素/孕激素受体状态、组织学分级、核分级、细胞外扩展、淋巴血管和神经周围侵犯以及受累淋巴结/切除淋巴结的比例)和治疗相关因素(PMRT、化疗和激素治疗)与 LRR 和 DM 率相关。分析了 5 年 Kaplan-Meier DFS 和 OS 率。
RT 组与非 RT 组在除 OS 外的所有比较中均存在统计学差异,均有利于 RT 组:LRR 率(3%比 17%,p = 0.038)、DM 率(12%比 42%,p = 0.004)、5 年 DFS(82.4%比 52.4%,p = 0.034)、5 年 OS(90.2%比 61.9%,p = 0.087)。多因素分析显示,DM 和淋巴管侵犯是 OS 的独立不良预后因素。
根据预后因素,T1-2、N1-3 阳性 BC 患者的 PMRT 必须重新考虑,并且必须在考虑长期发病率的情况下,与患者共同决定是否进行 PMRT。